ETON PHARMACEUTICALS INC. - COMMON STOCK

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

28 июл 2025 04:00:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

08 июл 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

27 июн 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

28 май 2025 14:28:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

14 май 2025 13:30:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

13 май 2025 13:01:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

01 май 2025 13:30:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

28 апр 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

01 апр 2025 04:00:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

18 мар 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

14 мар 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

04 мар 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

03 мар 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

07 фев 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

06 фев 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

03 янв 2025 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

20 дек 2024 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

17 дек 2024 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

03 дек 2024 03:50:00 Источник Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

25 ноя 2024 03:50:00 Источник Nasdaq GlobeNewswire